bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–09–27
eight papers selected by
Cliff Dominy



  1. Biomedicines. 2026 Sep 03. pii: 1989. [Epub ahead of print]14(9):
      Cardiovascular diseases remain a major cause of death and disability, and the limited regenerative capacity of the adult myocardium continues to constrain recovery after myocardial infarction, ischemia/reperfusion injury, cardiomyopathy, and heart failure. Small extracellular vesicles (sEVs), often described as exosome-enriched vesicle preparations, have emerged as promising cell-free mediators of cardioprotection and cardiac repair. This review evaluates the current experimental and translational evidence on sEVs in cardiac injury, including regulatory RNA and non-RNA cargo mechanisms, producer cell sources, preclinical injury models, engineered and biomaterial-assisted delivery strategies, and the development of clinically viable cell-free therapies. Across preclinical models, sEVs derived from mesenchymal stem cells, induced pluripotent stem cell-derived cardiac cells, cardiac progenitor cells, endothelial cells, cardiomyocytes, immune cells, and other sources have been associated with improved ventricular function, reduced infarct or scar size, enhanced angiogenesis, lower apoptosis, attenuated fibrosis, and modulation of post-injury inflammation. These effects are frequently associated with changes in, or enrichment of, microRNAs, long non-coding RNAs, and circular RNAs that regulate survival signaling, immune polarization, extracellular matrix remodeling, and endothelial recovery. Emerging evidence further suggests that proteins, lipids, and organelle-associated cargo, including mitochondrial components, also contribute to stress adaptation, vesicle biogenesis, mitochondrial homeostasis, and metabolic repair. However, the field remains limited by inconsistent nomenclature, variable isolation and characterization methods, heterogeneous producer cell sources, uncertain potency assays, incomplete biodistribution data, and unresolved regulatory classification. Overall, sEV-based therapy represents a compelling but still developing approach to cardiac repair. Within this framework, functional recovery is treated as an outcome of cardioprotection, cardiac repair, or, where supported, myocardial regeneration; regeneration is reserved for evidence of newly formed and functionally integrated myocardium. Future progress will depend on better product definition, mechanism-linked potency testing, scalable manufacturing, and delivery strategies matched to specific cardiac indications.
    Keywords:  biomaterial-assisted delivery; cardiac repair; cardioprotection; cardiovascular disease; cargo mechanisms; exosome; miRNA; small extracellular vesicles
    DOI:  https://doi.org/10.3390/biomedicines14091989
  2. Int J Mol Sci. 2026 Sep 21. pii: 8431. [Epub ahead of print]27(18):
      Cardiovascular diseases (CVDs) are the most prevalent cause of mortality globally, despite decades of targeted treatment of known risk factors including hypercholesterolemia. This review summarizes recent work on other lipids beyond cholesterol that may also contribute to CVD and serve as novel therapeutic targets. In particular, work on extracellular vesicles (EVs), which are membrane-delimited particles released by many cell types, suggests that lipid classes such as sphingolipids, phospholipids, and glycosylated lipids may contribute to CVD progression. EVs are particularly interesting due to their high biocompatibility, specific targeting, and diverse payloads. They enable intercellular communication through the transfer of lipids, proteins, and nucleic acids. Changes in EV lipid composition are highly dependent on the cellular environment, potentially enabling their use as biomarkers. While most of the published body of work on EVs is focused on protein and miRNA cargo, recent advances in metabolomic techniques enable the probing of changes in distinct EV lipid profiles associated with CVD. Herein, we summarize EV lipid work of the last five years that reaches beyond cholesterol and triglycerides and describe known lipid function in EVs and CVD. More research is needed to determine exactly how changing lipid loads of EVs impact the cardiovascular system, and how EVs and their selective lipid cargo may offer a novel approach for the treatment and diagnosis of CVD.
    Keywords:  cardiovascular disease; extracellular vesicles; lipid species; lipidomics
    DOI:  https://doi.org/10.3390/ijms27188431
  3. Front Bioeng Biotechnol. 2026 ;14 1941420
      Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide and impose a substantial clinical and socioeconomic burden. Despite advances in medical, interventional, and surgical treatments, considerable residual cardiovascular risk persists, highlighting the need for effective and sustainable therapeutic approaches. Milk-derived extracellular vesicles (MDEVs) are heterogeneous lipid-bilayer vesicles present in human and bovine milk and have attracted increasing interest as potential orally administered biological nanocarriers. MDEVs carry diverse bioactive cargo, including proteins, lipids, messenger RNAs, microRNAs, and long non-coding RNAs, while their membrane-associated components may contribute to gastrointestinal stability, cargo protection, and interactions with intestinal cells. Emerging preclinical evidence suggests that MDEVs may influence inflammatory responses, oxidative stress, myocardial fibrosis, angiogenesis, and gut-heart axis signaling. However, direct evidence from cardiovascular disease models remains limited, and several proposed mechanisms are supported primarily by studies conducted in intestinal, metabolic, oncological, or other non-cardiovascular settings. MDEVs can also be engineered to carry nucleic acids, peptides, proteins, and small-molecule drugs or to introduce tissue-targeting properties. Nevertheless, their systemic absorption, biodistribution, cardiovascular tissue accumulation, and long-term safety after oral administration remain insufficiently defined. Moreover, milk source, processing conditions, isolation methods, co-isolated non-vesicular components, cargo composition, dose metrics, administration routes, and disease models may substantially affect the reported biological effects. Continued advances in purification, standardized characterization, rigorous biodistribution analysis, safety assessment, and scalable manufacturing are therefore required to determine the translational potential of MDEVs in cardiovascular therapy.
    Keywords:  cardiovascular diseases; engineered extracellular vesicles; gut–heart axis; milk-derived extracellular vesicles; nanocarriers; oral delivery; therapeutic delivery
    DOI:  https://doi.org/10.3389/fbioe.2026.1941420
  4. Biomedicines. 2026 Sep 05. pii: 2002. [Epub ahead of print]14(9):
      Background/Objectives: Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication in cardiovascular disease, particularly through the transfer of regulatory microRNAs. However, direct evidence of cytosolic microRNA delivery by mesenchymal stem cell (MSC)-derived EVs into cardiomyocytes remains limited. Many prior studies have inferred transfer without fully excluding endogenous microRNA induction or surface-bound artifacts. The objective of this study was to determine whether MSC-derived EV microRNA undergoes functional cytoplasmic delivery into cardiomyocytes and to identify the endocytic pathways involved. Methods: To eliminate background from endogenous microRNA expression, MSC-derived EVs were loaded with the exogenous microRNA cel-miR-39-3p. H9C2 cardiomyocytes were treated with increasing vesicle doses, and intracellular microRNA levels were quantified using real-time polymerase chain reactions. Cytosolic accessibility was assessed indirectly using a cholesterol-modified antagomir targeting cel-miR-39-3p. Pharmacologic inhibitors of macropinocytosis (5-(N-ethyl-N-isopropyl) amiloride (EIPA)) and clathrin-mediated endocytosis (chlorpromazine and ES9-17) were applied to delineate uptake pathways, with transferrin assays confirming clathrin inhibition. Results: EV treatment produced a dose-dependent increase in intracellular cel-miR-39-3p levels. Antagomir administration reduced intracellular microRNA levels by 89%, providing indirect functional evidence that transferred cel-miR-39-3p reached an antagomir-accessible cytosolic compartment. At the highest preparation dose, EIPA and ES9-17 reduced cell-associated cel-miR-39-3p by 71% and 36%, respectively, consistent with contributions from EIPA-sensitive and clathrin-associated uptake processes. Notably, chlorpromazine increased microRNA accumulation despite blocking transferrin uptake, suggesting compensatory or membrane curvature-dependent effects. Conclusions: These findings provide strong functional evidence that exogenous cel-miR-39-3p associated with MSC EV preparations reaches an antagomir-accessible cytoplasmic compartment in H9C2 cardiomyocytes and implicate EIPA-sensitive uptake consistent with macropinocytosis and clathrin-associated uptake. Additional genetic, localization, and pulse-chase studies are required to establish the precise intracellular trafficking mechanisms. This work strengthens the mechanistic foundation for EV-based therapies and informs the rational development of cell-free strategies for cardiovascular disease.
    Keywords:  cardiovascular disease; endocytosis; exosomes; extracellular vesicles; microRNA
    DOI:  https://doi.org/10.3390/biomedicines14092002
  5. Expert Rev Cardiovasc Ther. 2026 Sep 24. 1-15
       INTRODUCTION: Heart failure (HF) is one of the most urgent unmet challenges in cardiovascular medicine. Despite advances in guideline-directed medical therapy (GDMT), substantial morbidity and mortality remain high in patients with advanced disease. This suggests a need for disease-modifying interventions that address underlying biological mechanisms.
    AREAS COVERED: This review examines the mechanistic evolution of cardiac cell therapy, from the original engraftment-and-differentiation paradigm to paracrine and immunomodulatory frameworks. Based on a PubMed and ClinicalTrials.gov search (January 2000 - June 2026), we discuss advances in mesenchymal stem cells, extracellular vesicles, CRISPR-based gene editing, and emerging precision medicine strategies including multi-omics profiling, machine learning-based patient stratification, and adaptive trial design.
    EXPERT OPINION: Meaningful clinical progress will require matching biologically informed cell or cell-free products to genetically and phenotypically defined patient subgroups, adopting repeat-dosing paradigms, and integrating regenerative therapies within the existing heart failure treatment framework rather than deploying them as standalone interventions. If these approaches are implemented successfully, cell-based regenerative therapies will have the potential to substantially impact the prognosis and treatment of HF.
    Keywords:  Heart failure; cardiovascular disease; mesenchymal stem cells; precision medicine; regenerative medicine
    DOI:  https://doi.org/10.1080/14779072.2026.2735936
  6. Front Neurosci. 2026 ;20 1942262
      Coronary heart disease (CHD) is commonly conceptualized as a disorder of atherosclerotic plaque burden, myocardial oxygen supply-demand mismatch and thrombosis. This framework remains indispensable, yet it does not fully explain stress-induced ischemia, persistent symptoms in the absence of obstructive lesions, or neuropsychiatric and cognitive sequelae after acute coronary events. Evidence increasingly indicates that CHD is embedded in a bidirectional brain-heart axis in which central autonomic, neuroendocrine, immune, vascular, metabolic, sleep-circadian and extracellular vesicle-mediated signals interact over time. In the brain-to-heart direction, psychological stress and altered activity within central autonomic networks may promote sympathetic activation, vagal withdrawal, hypothalamic-pituitary-adrenal signaling, endothelial dysfunction, platelet activation, coronary microvascular dysregulation and inflammatory acceleration of atherosclerosis. Mental stress-induced myocardial ischemia is a clinically relevant example of this top-down pathway and has been associated with adverse outcomes in patients with established CHD. In the heart-to-brain direction, coronary ischemia and myocardial infarction may affect brain function through visceral afferent signaling, systemic and neuroinflammation, cerebral hypoperfusion, blood-brain barrier disruption and cardiac extracellular vesicles. These processes may contribute to depression, anxiety, cognitive impairment and altered interoceptive control after acute coronary events, thereby creating feedback loops that can worsen cardiovascular risk. This review critically synthesizes clinical, observational, neuroimaging, and experimental evidence concerning CHD as a bidirectional brain-heart axis disorder. We distinguish established clinical associations from emerging mechanistic pathways, highlight major methodological limitations and unresolved controversies, and discuss the current level of evidence supporting candidate biomarkers and therapeutic strategies. We argue that future CHD management should complement plaque- and ischemia-oriented strategies with assessment of autonomic function, mental health, inflammatory tone, sleep-circadian biology, cerebrovascular health and neuroimmune signaling. Such integration may help identify patients whose risk is driven not only by coronary anatomy, but also by maladaptive brain-heart communication.
    Keywords:  brain–heart axis; central autonomic network; coronary heart disease; mental stress-induced myocardial ischemia; neuroinflammation
    DOI:  https://doi.org/10.3389/fnins.2026.1942262
  7. Stem Cell Res Ther. 2026 Aug 08. pii: 339. [Epub ahead of print]17(1):
      Ischemic stroke remains a major global health burden because of its high incidence, disability, and mortality. Current reperfusion therapies are constrained by narrow therapeutic windows and have limited capacity to reverse established neuronal injury or promote long-term functional recovery, highlighting the need for strategies that support neural repair and neurovascular remodeling. Bone marrow-derived mesenchymal stem cells (BMSCs) have been widely investigated as candidate therapeutic products for ischemic stroke because of their paracrine, immunomodulatory, trophic, angiogenic, and microenvironment-regulating properties. Current evidence suggests that their therapeutic effects are more likely mediated by regulation of the post-ischemic microenvironment than by direct neuronal replacement. This narrative review discusses BMSC-based strategies for ischemic stroke by integrating evidence from preclinical models, early clinical studies, and translational research. We summarize major proposed mechanisms, including regulation of neuroinflammation, suppression of apoptosis and oxidative stress, blood-brain barrier protection, angiogenesis, neurotrophic support, axonal remodeling, and myelin repair. Emerging mechanisms, such as autophagy regulation, mitochondrial transfer, and extracellular vesicle-mediated effects, are also discussed according to their current level of evidence. In addition, this review evaluates delivery routes, functional enhancement strategies, BMSC-derived extracellular vesicles, combination approaches, clinical evidence, and key translational barriers. Particular attention is given to the distinction between experimentally supported mechanisms, early clinical safety and feasibility signals, and unresolved issues related to optimal dose, administration timing, route-dependent biodistribution, product heterogeneity, mechanism-linked potency assays, and Good Manufacturing Practice-compatible manufacturing. This review provides a balanced framework for understanding the therapeutic potential, current limitations, and future development requirements of BMSC-based therapies for ischemic stroke.
    Keywords:  Bone marrow mesenchymal stem cells; Combined utilization; Delivery systems; Functional enhancement strategy; Ischemic stroke; Transplantation methods
    DOI:  https://doi.org/10.1186/s13287-026-05219-7
  8. Noncoding RNA. 2026 Aug 24. pii: 32. [Epub ahead of print]12(5):
      Background: Cerebrovascular diseases have complex pathogenesis and pose a serious threat to human health; thus, novel diagnostic and therapeutic strategies are needed. Small extracellular vesicles (sEVs), commonly referred to as exosomes, are 30-150 nm lipid-bilayer vesicles that shield long noncoding RNAs (lncRNAs) from degradation. Because exosomal lncRNAs are more stable than free lncRNAs in blood and cerebrospinal fluid and can cross the blood-brain barrier, they are promising as biomarkers and therapeutic vectors. This review summarizes the roles and mechanisms of exosomal lncRNAs in cerebrovascular diseases. Methods: This narrative review is based on the experimental literature and focuses on the biological functions and regulatory mechanisms of exosomal lncRNAs in cerebrovascular disorders. Results: As competing endogenous RNAs (ceRNAs), they sequester microRNAs (miRNAs), thereby derepressing downstream target-gene expression and modulating neuronal injury (oxidative stress, apoptosis, neuroinflammation) through the nuclear factor kappa-B (NF-κB) and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathways. They show altered profiles in acute stroke (ischemic/hemorrhagic) correlated with neurological deficits, and are relevant to the early diagnosis of chronic diseases (atherosclerosis, aneurysm) and vascular dementia. Conclusions: Exosomal lncRNAs demonstrate promising translational potential in preclinical studies because they combine exosome delivery capabilities with lncRNA regulatory functions, although clinical validation remains limited.
    Keywords:  atherosclerosis; biomarkers; cerebrovascular diseases; exosomal lncRNAs; ischemic stroke
    DOI:  https://doi.org/10.3390/ncrna12050032